SCHEMBL22049686

SCHEMBL22049686

COC(=O)c1ccc2c(n1)[C@@H](C)CCN2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.36
PARP1 P09874 1/20 0.33
CYP1A2 P05177 3/20 0.33
MAPT P10636 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
CYP2C9 P11712 2/20 0.33
PTGER4 P35408 1/20 0.33
GAA P10253 1/20 0.33
RECQL P46063 1/20 0.33
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PLAT P00750 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
F2 P00734 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22049689 1.00 MAPK1 (0.36) MAPK1PARP1CYP1A2MAPTNPC1
SCHEMBL22049690 1.00 MAPK1 (0.36) MAPK1PARP1CYP1A2MAPTNPC1
SCHEMBL30158223 1.00 MAPK1 (0.36) MAPK1PARP1CYP1A2MAPTNPC1
SCHEMBL20571701 0.84 KDM4E (0.37) MAPTRAB9ASMN1; SMN2KMT2AL3MBTL1
SCHEMBL20571678 0.84 KDM4E (0.37) MAPTRAB9ASMN1; SMN2KMT2AL3MBTL1
SCHEMBL20571031 0.84 KDM4E (0.37) MAPTRAB9ASMN1; SMN2KMT2AL3MBTL1
SCHEMBL31000274 0.83 BRD4 (0.37) PARP1HPGD
SCHEMBL7671170 0.77 CYP1A2 (0.41) MAPK1CYP1A2MAPTNPC1RAB9A
SCHEMBL287974 0.74 MAPK1 (0.39) MAPK1PARP1CYP1A2MAPTNPC1
SCHEMBL20571711 0.71 GAA (0.39) MAPK1PARP1CYP1A2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3630770-B1 PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS RELAY THERAPEUTICS INC (US) 2024-08-28 EP disclosed
US-11591336-B2 Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors D. E. SHAW RESEARCH, LLC (US) 2023-02-28 US disclosed
US-20200172546-A1 PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS RELAY THERAPEUTICS, INC. 2020-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172546-A1 PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS PTPRJ, PTPN2, PTPN5 MAPK1 562/4885PARP1 4150/4885CYP1A2 3695/4885
US-11591336-B2 Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors PTPN5, PTPN2, PTPN1 MAPK1 304/4885PARP1 4513/4885CYP1A2 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.